The diagnosis of amyotrophic lateral sclerosis can be challenging due to its heterogeneity in
clinical presentation and overlap with other neurological disorders. Diagnosis early in the …

Disease heterogeneity in amyotrophic lateral sclerosis poses a substantial challenge in drug
development. Categorization based on clinical features alone can help us predict the …

Bulbar impairment represents a hallmark feature of Amyotrophic Lateral Sclerosis (ALS) that
significantly impacts survival and quality of life. Speech and swallowing dysfunction are key …

Amyotrophic lateral sclerosis is a neurodegenerative disease predominantly affecting upper
and lower motor neurons, resulting in progressive paralysis and death from respiratory …

Amyotrophic lateral sclerosis is a progressive and devastating neurodegenerative disease.
Despite decades of clinical trials, effective disease-modifying drugs remain scarce. To …

Abstract Background The ALS Functional Rating Scale in its revised version (ALSFRS-R) is
a disease-specific severity score that reflects motor impairment and functional deterioration …

Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder with
complex biology and significant clinical heterogeneity. Many preclinical and early phase …

Despite the urgent, unmet clinical and economic need for treatment of neurodegenerative
diseases, trials of disease modifying drugs have produced little success. Amyotrophic lateral …

Background With increasing recognition of the value of incorporating prognostic markers
into amyotrophic lateral sclerosis (ALS) trial design and analysis plans, there is a pressing …

Amyotrophic lateral sclerosis (ALS) encompasses a heterogeneous group of phenotypes
with different progression rates, varying degree of extra-motor involvement and divergent …